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Abstract
Ribavirin (RBV) is a synthetic nucleoside analog with broad spectrum antiviral activity. Although RBV is approved for the
treatment of hepatitis C virus, respiratory syncytial virus, and Lassa fever virus infections, its mechanism of action and
therapeutic efficacy remains highly controversial. Recent reports show that the development of cell-based resistance after
continuous RBV treatment via decreased RBV uptake can greatly limit its efficacy. Here, we examined whether certain cell
types are naturally resistant to RBV even without prior drug exposure. Seven different cell lines from various host species
were compared for RBV antiviral activity against two nonsegmented negative-strand RNA viruses, vesicular stomatitis virus
(VSV, a rhabdovirus) and Sendai virus (SeV, a paramyxovirus). Our results show striking differences between cell types in
their response to RBV, ranging from virtually no antiviral effect to very effective inhibition of viral replication. Despite
differences in viral replication kinetics for VSV and SeV in the seven cell lines, the observed pattern of RBV resistance was
very similar for both viruses, suggesting that cellular rather than viral determinants play a major role in this resistance. While
none of the tested cell lines was defective in RBV uptake, dramatic variations were observed in the long-term accumulation
of RBV in different cell types, and it correlated with the antiviral efficacy of RBV. While addition of guanosine neutralized RBV
only in cells already highly resistant to RBV, actinomycin D almost completely reversed the RBV effect (but not uptake) in all
cell lines. Together, our data suggest that RBV may inhibit the same virus via different mechanisms in different cell types
depending on the intracellular RBV metabolism. Our results strongly point out the importance of using multiple cell lines of
different origin when antiviral efficacy and potency are examined for new as well as established drugs in vitro.
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Introduction
Ribavirin (RBV, also known as virazole), 1-ß-D-ribofuranosyl-
1,2,4-triazole-3-carboxamide, is the first synthetic, broad-spectrum
antiviral nucleoside analog [1], which has been shown to exhibit
antiviral activity against many RNA and DNA viruses both in
vitro and in vivo [2,3,4,5]. RBV was originally approved for the
treatment of respiratory syncytial virus (RSV) infection in children,
and today is also used to treat Lassa fever and, most importantly,
hepatitis C virus (HCV) infections of humans [4]. While RBV
alone has little or no effect on viral replication in HCV patients
[6], it dramatically improves long-term antiviral response in many
treated patients when used in combination with interferon (IFN)
[3,4]. The mechanism of synergy between RBV and IFN [7,8],
which is critical for successful anti-HCV therapy, remains unclear
[4].
Despite these successes with RBV/IFN combination therapy
resulting in a so called sustained virological response (SVR, no
detectable plasma HCV RNA during treatment and for at least 6
months after therapy) or end-of-treatment response (ETR, HCV
RNA is undetectable when therapy is terminated), a large portion
of patients are ‘‘non-responders’’ (detectable HCV RNA through-
out the treatment period). The mechanism of non-response to
RBV/IFN treatment is very controversial and, unfortunately, no
alternative therapies available for non-responders.
The understanding of RBV treatment failures is complicated by
an unclear mechanism of RBV action, partly due to its apparent
pleiotropic nature [3,4]. Upon uptake, RBV is metabolized in vivo
through 59-phosphorylation by cellular kinases into ribavirin
mono- (RMP), di- (RDP) and triphosphate (RTP) [9,10,11]. Six
distinct mechanisms (which may work together) have been
proposed for antiviral action of RBV against different viruses
[2,3,4,5]: i) inhibition of the host enzyme inosine monophosphate
dehydrogenase (IMPDH) essential for the de novo synthesis of GTP;
ii) direct interaction of phosphorylated RBV with and inhibition of
viral RNA polymerase, iii) RNA chain termination as a result of
incorporation of RTP (GTP analog) into replicating RNA strands
by viral RNA polymerases; iv) ‘‘error catastrophe’’ as a result of
RTP incorporation into the viral genome paired with cytidine and
uridine as a substitute for guanine and/or adenine, resulting in so
called ‘‘lethal mutagenesis’’, a meltdown of genetic information; v)
inhibition of mRNA capping; and vi) immunomodulation of
antiviral cellular responses such as the ability to induce a Th2 to
Th1 shift in the immune response.
Previous studies in search of explanations for RBV treatment
failures were largely focused on the role of viral determinants of
RBV resistance [5,6], as any antiviral mechanism of RBV via
direct interactions with the viral RNA polymerase can hypothet-
ically be overcome by mutations in the viral RNA polymerase.
Such an escape via a single mutation in the RNA-dependent RNA
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increased polymerase fidelity in poliovirus [5,12] and foot-and-
mouth disease virus [13,14].
While drug resistant viral mutants may explain at least some
failures with RBV treatments, recent reports propose that cell-based
resistance to RBV could be an important factor explaining the low
antiviral activity of RBV in at least some experimental and clinical
systems [6]. For example, Pfeiffer and Kirkegaard provided in vitro
evidence that resistance of infected cells to RBV can be conferred
not only via mutations in the viral genome (‘‘virus-based resistance’’)
but also through changes in the RBV treated cells (‘‘cell-based
resistance’’) [12,15]. A recent study by Ibarra and Pfeiffer [16] shows
that the development of cell-based resistance to RBV treatment via
decreased RBV uptake can greatly limit RBV antiviral activity.
To examine whether certain cell types are naturally resistant to
RBV even without prior drug exposure, we selected seven different
cell lines from various hosts and compared them for the antiviral
activities of RBV against two nonsegmented negative-strand RNA
viruses (order Mononegavirales), vesicular stomatitis virus (VSV,
family Rhabdoviridae) and Sendai virus (SeV, family Paramyxoviridae),
which were previously shown to be highly sensitive to RBV
treatment [17,18,19,20,21]. Our results show dramatic cell-type
dependent differences in the antiviral activities of RBV, ranging
from virtually no effect to very effective inhibition of viral
replication, indicating that some cell types are naturally resistant
to RBV treatment even without prior exposure to this drug. The
data presented in this study shed light on the mechanisms of the
RBV activity against VSV and SeV, and may explain at least some
of the reported failures with RBV treatments.
Materials and Methods
Cell lines and viruses
The following seven cell lines were used in this study: Syrian
golden hamster kidney fibroblast cells (BHK21, ATCC# CCL-10);
human cervical adenocarcinoma cells (HeLA, ATCC# CCL-2);
human epithelial lung carcinoma cells (A549, ATCC# CCL-185),
mouse mammary gland adenocarcinoma cells (4T1, ATCC#
CRL-2539), human epidermal carcinoma cells (HEp2, ATCC#
CCL-23); and African green monkey kidney cells (Vero, ATCC#
CCL-81). In addition, we used BSRT7 cells which are derived from
BHK21, constitutively express bacteriophage T7 polymerase and
described by Buchholz et al. [22]. Monolayer cultures of these cell
lines were maintained in Minimum Essential Medium (Eagle’s
MEM, Cellgro) or Dulbecco’s modified Eagle’s medium (DMEM,
Cellgro) supplemented with 9% fetal bovine serum (FBS, Gibco) in
a5 %C O 2 atmosphere at 37uC. VSV-GFP is a recombinant wild
type (wt) VSV (Indiana serotype) encoding GFP as an extra gene
between the G and L genes [23], kindly provided by Dr. Asit K.
Pattnaik (University of Nebraska). Recombinant SeV-GFP (Fushimi
strain) encoding GFP upstream of the NP gene [24] was kindly
provided by Dr. Wolfgang J. Neubert (Max-Planck-Institute of
Biochemistry,Germany).To grow VSV-GFP or SeV-GFP,BHK21
or Vero cells, respectively, were infected with viruses at a
multiplicity of infection (MOI) of 0.05 CIU (cell infectious units)
per cell in MegaVir HyQSFM4 serum-free medium (SFM,
Hyclone) and incubated for 24–48 h at 34uC. This temperature
(34uC) was chosenas itsupportedoptimal replicationof both viruses
in the seven cell lines (data not shown) and all virus infections
presented in this study were conducted at 34uC. SeV-GFP was
grown without acetylated trypsin in the medium as it has the wt
monobasic trypsin-dependent cleavage site in the F protein mutated
to an oligobasic cleavage site, allowing F activation in any cell type
through an ubiquitous furin-like protease [24].
Inhibitors
RBV was purchased from MP Biomedicals (cat. no. 196066);
guanosine (cat. no. 101907) and actinomycin D (ActD) (cat.
no. 10465805) from MP Biomedicals; and S-(4-Nitrobenzyl)-6-
thioinosine (NBMPR, also known as NBTI, cat. no. N2255) from
Sigma-Aldrich. Stock solution of RBV (0.1 M) was made in H2O,
while ActD (2 mg/ml) was dissolved in 100% ethyl alcohol, and
guanosine (20 mM) and NBMPR (16.8 mM) in DMSO.
Virus infections in the presence of inhibitors
Most experiments were conducted using 24-well tissue culture
plates and nearly 100% confluent cells treated with drugs in SFM
(or mock-treated with SFM) and infected with VSV-GFP or SeV-
GFP (or mock-infected with SFM) at MOI of 3 CIU/cell. The
MOI for each virus/cell type combination was calculated by
infecting each cell line with VSV-GFP or SeV-GFP serial dilutions
in SFM and counting infectious foci with the aid of fluorescence
microscopy. RBV was added to the cells at 24 h before infection.
After absorption of virus for 1 h in the absence of drugs (to rule out
an interference of drugs with virus attachment/entry), SFM
containing unabsorbed virus was removed, cells were washed three
times with phosphate-buffered saline (PBS), and 300 ml/well of
SFM with the same concentrations of drugs as in the pretreatment
was added to each well. The fluorescence and bright field
photographs of cells at 106magnification were captured 24 h post
infection (p.i.) or 48 h p.i. using an Olympus DP70 digital camera
mounted on an Olympus IX71 inverted fluorescent microscope
and Olympus DP Controller software. To examine effect of RBV
on virus production, SFM containing infectious particles was
collected 24 or 48 h p.i., and viral titrations were performed in 96-
well plate format by infecting BHK21 (for VSV) or Vero cells (for
SeV) with serial virus dilutions. For SeV titration, cells were
overlaid with 100 ml SFM containing 1.2% Avicel RC-581 (FMC
BioPolymer, Philadelphia, PA) as previously described [25], while
a 0.56 SFM/1% bactoagar mixture was used to overlay VSV-
infected cells.
The effect of the exogenously added guanosine on VSV and
SeV replication in the presence or absence of RBV was examined
using confluent monolayers of cells in 96-well tissue culture plates
(performed three times, done in triplicates). Cells were infected
with either VSV-GFP or SeV-GFP (or mock-infected with SFM)
at MOI of 3 CIU/cell. After 1 h p.i., virus was removed and cells
were washed with PBS, and mock-treated or treated with the SFM
containing 500 mM RBV or 50 mM guanosine, or RBV together
with guanosine. Guanosine was dissolved in DMSO and the final
concentration of DMSO in the media added to all wells was
0.25%. The intensity of fluorescent signal at 18 h p.i for VSV and
24 h p.i for SeV was quantified using a Fluorescence Multi-Well
Plate Reader CytoFluor 4000 (PerSeptive Biosystems, Inc.,
Framingham, MA) with the standard in built Cyto Fluor filter
set (excitation wavelength at 485 and emission wavelength at
530 nm). Values were corrected for background fluorescence by
subtracting the values of uninfected cells from the value of each
infected well.
Plaque reduction assay to determine RBV inhibitory
concentrations
To estimate the 50% and 90% inhibitory concentrations (IC50
and IC90) for RBV, antiviral screening was conductedby means of a
plaque reduction assay using 24-well tissue culture plates. Cells were
infected with VSV-GFP or SeV-GFP in SFM (or mock-infected
with SFM) at an MOI producing about 100 virus plaques per well
on each cell line in the absence of RBV. After absorption of virus for
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entry), SFM containing unabsorbed virus was removed, cells were
washed three times with phosphate-buffered saline (PBS), and
overlaid with 200 ml/well of SFM containing 1.2% Avicel RC-581
and increasing concentrations of RBV. Cells were then incubated
for 24 h (VSV) or 48 h (SeV). Plaques were counted with the aid of
fluorescence and bright field microscopy, and the 50% (IC50)a n d
90% (IC90) inhibitory concentrations were calculated. Initial
experiments were done using 0, 200, 500 or 1000 mM of RBV as
it was done for virus infections at MOI 3 to determine the range of
RBV activity for each virus/cell line combination. After that, all
plaque reduction experiments were conducted using different
ranges of RBV concentrations to more precisely determine the
IC50 and IC90 values. Each of these experiments was performed at
least twice (done in duplicates) and plaque numbers represent the
mean 6 standard deviation of the mean.
Virus growth analysis
The relative efficiency of the initiation of infection by VSV-GFP
and SeV-GFP was measured by titrating viruses on the seven cell
lines to determine the number of viral particles successfully
initiating infection in a given cell line. For one-step growth kinetics
analysis, confluent cell monolayers in 24-well plates were infected
in parallel at an MOI of 3 CIU/cell. At 1 h p.i., infection medium
was aspirated, cells were washed three times with PBS (to
minimize carryover of virions), and 300 ml of fresh SFM was
added to each well. SFM from each well was collected at the
specified time intervals, flash frozen at 280uC, and analyzed by
titration as described above.
RBV uptake assay
Cell monolayers were prepared exactly as for virus infections
using 12- or 24-well tissue culture plates. The [
3H]RBV uptake
experiments were conducted essentially as in [16] but with some
modifications. Cells were plated the day prior to generate about
90% confluence on the day of the experiment. For RBV uptake in
the presence or absence of NBMPR (15 or 100 mM), cells (in
triplicates) on 24-well plates were pretreated with this nucleoside
transporter inhibitor in DMSO (or with DMSO alone) for
15 minutes. Cells were then washed with PBS and treated with
100 ml of SFM (same medium used for infections but without
virus) containing 50 mM RBV 1% of which was [
3H]RBV
(ViTRax, Placentia, CA, cat. no. VT193, specific activity 5 Ci/
mmol) for 15 minutes in a 5% CO2 atmosphere at 37uC. For the
long-term accumulation of RBV, cells (in triplicates) on 12-well
plates were washed with PBS and treated with 275 ml of SFM
(same medium used for infections but without virus) containing the
same concentration of RBV/[
3H]RBV (in the absence of
NBMPR) as above but incubated for 1 h, 16 h or 24 h. To
measure intracellular [
3H]RBV, cells were then placed on ice for
5 minutes (to stop an uptake) and washed 3 times with cold PBS.
The cells were then trypsinized, pelleted at 2006g for 4 minutes
and cell pellets were frozen at 280uC. Nucleotide pool isolation
was conducted as described in [26]. Specifically, tubes with frozen
cell pellets were placed on ice and 75 ml of 1.3 N cold formic acid
was added to each pellet, cell pellets were resuspended in formic
acid and incubated for 1 h (tubes were vortexed every 15 minutes)
on ice. After 1 h extraction period, the formic acid suspension was
centrifuged at 17,0006g, and the supernatant extracts (75 ml) were
transferred to new tubes and quantified (15 ml) by scintillation
counting for the intracellular [
3H] accumulation. Cell numbers
(from separate plates) were counted by two separate methods.
First, cells were trypsinized and cell number was determined using
a hemocytometer. Cell numbers were independently confirmed by
staining monolayers (from a separate plate) with blue-fluorescent
Hoechst 33342 dye (Invitrogen), which selectively stains nuclei. At
least 5 random fields were photographed using a fluorescence
microscope and DAPI filter and nuclei were then counted. Uptake
values were determined by dividing the counts per minute (CPM)
by number of cells (CPM/cell) in a 24-well plate. For RBV uptake
in the presence of ActD, cells were pretreated with 5 mg/ml ActD
for 2 h, media was aspirated (without cell washing), and then RBV
uptake assay was conducted as described above.
Cell viability assays
Cellular toxicity of RBV was determined using about 80%
confluent cells treated with increasing RBV concentrations (0, 200,
500 or 1000 mM) at 37uC and 5% CO2 for 24 h. After 24 h, all
cells reached 100% confluence and were analyzed by the following
three assays: i) MTT (Biotium, cat. no. 30006, 96-well plate
format) cell viability assay; ii) CellTiter-Glo luminescent cell
viability assay (Promega cat. no. G7570, 96-well plate format); and
iii) cell counting using trypan blue dye exclusion as an indicator of
live cells (24-well plate format). MTT assay was conducted
according to the manufacturer’s (Biotium) protocol. Briefly, after
24 h incubation with RBV, 10 ml of MTT solution was added to
each well and cells were incubated for 4 h at 37uC. Media was
then removed and 200 ml of DMSO added to each well. OD
values were measured using a Multiskan Ascent Microplate
Photometer (Thermo Fisher Scientific) at a test wavelength of
570 nm and reference wavelength of 630 nm to determine the
OD570–OD630 signal. CellTiter-Glo assay was conducted accord-
ing to the manufacturer’s (Promega) protocol and using 96-well
white opaque culture plates (PerkinElmer, cat. no. 6005680). After
24 h incubation with RBV, 100 ml of CellTiter-Glo reagent was
added to each well, plates were mixed for 2 minutes on orbital
shaker to induce cell lysis, and incubated for 10 minutes to
stabilize the luminescence signal. Luminescence was measured
using Perkin Elmer TopCount NXT microplate luminescence
counter. For trypan blue dye exclusion, 24-well plates were used.
After 24 h incubation with RBV, cells were trypsinized and the
number of viable cells was determined microscopically in a
hemacytometer by trypan blue exclusion.
Results
Identification of RBV-resistant cell lines
To determine whether ‘‘natural’’ (without pre-exposure to drug)
resistance to RBV exists in some cell types, we selected seven
commonly used cell lines (BHK21, BSRT7, HeLa, A549, 4T1,
HEp2, and Vero) originated from various hosts and tissues, and
compared them for the antiviral activity of RBV against VSV and
SeV. To facilitate virus detection, we employed recombinant
viruses containing an additionally inserted GFP gene (Fig. 1A).
While such insertion results in a mild attenuation of VSV [23] and
SeV [24,27], both viruses replicate similarly to parental wt strains
(data not shown) and, thus, serve as useful models for studying
replication of wt viruses. Cells were treated with increasing
concentrations of RBV added to the media 24 h before infection,
and then infected with viruses at MOI of 3 CIU/cell with RBV
treatment continued after virus absorption. The MOI for each cell
line was calculated individually by titrating viruses on each of the
seven cell lines as described in Materials and Methods and Table 1.
Following RBV treatment and virus infection, pictures were taken
24 h post infection (p.i.) for VSV or 48 h p.i. for SeV using
fluorescence and light microscopy. As shown in Figure 1B, GFP-
associated fluorescence attributable to viral replication was readily
detectable in all tested cells lines infected with VSV or SeV when
Ribavirin Resistance of Cells
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susceptible to infection by these two viruses. Consistent with
previous studies demonstrating antiviral activity of RBV against
VSV, RBV effectively inhibited VSV in BSRT7, HeLa and HEp2
cells even at the lowest (200 mM) tested drug concentration
(Fig. 1B). However, RBV had a surprisingly mild effect on the
VSV-driven GFP expression in BHK21, Vero and A549 cells even
when used at 1000 mM concentration with a somewhat interme-
diate effect in 4T1 cells (Fig. 1B). In general, RBV inhibited SeV
replication to a greater degree than VSV with markedly stronger
inhibition in 4T1 cells. However, Figure 1B clearly shows a similar
pattern of RBV resistance in BHK21, Vero and A549 cells for
VSV and SeV, suggesting that cellular rather than virus-specific
factors determine the dramatic differences between tested cell lines
in their response to RBV. A similar pattern was also observed
when RBV was added to the medium 6 h (rather than 24 h) before
or 1 h after infection (without RBV pretreatment), although in
general RBV was more effective when longer pretreatments were
conducted (data not shown). In addition, a similar pattern of RBV
effect in the seven cell lines was observed when experiments were
conducted at 37uC rather than at 34uC [34uC was chosen for
experiments presented here as it supported optimal replication of
Figure 1. Effect of RBV on viral replication in seven cell lines. (A) The organization of the negative-sense RNA genomes of the recombinant
viruses used in this study. (B) The panels show photographs of cells pretreated for 24 h with increasing concentrations of RBV as indicated (or mock-
treated), infected with VSV-GFP (left) or SeV-GFP (right) at MOI 3 CIU/cell (or mock-infected, upper row), and then the same concentrations of drugs as
in the pretreatment was added to each well after virus absorption. Fluorescence (upper panels) and light (lower panels) microscopy images were
captured at 106magnification. The photographs are typical representations of at least three independent experiments and an average field for each
well is shown. (C) Media from the experiments described in B was collected at 24 h p.i for VSV (left) or at 48 h p.i for SeV (right) and virus titer was
determined by standard plaque assay on BHK21 (for VSV) or Vero cells (for SeV). The data represent the mean 6 standard deviation of two
independent experiments (done in duplicates). Statistical analysis was done using one-way ANOVA with Tukey’s post hoc test (GraphPad Prism 4, San
Diego, CA). RBV treatments without significant decrease in viral titer at any tested RBV concentrations as compared to mock-treated cells (‘‘0 mM
RBV’’) are indicated as P.0.05.
doi:10.1371/journal.pone.0011265.g001
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various passage level (3 to 20 passages) or confluence (70%),
demonstrating that the observed effect was not determined by the
state of the cells (data not shown).
To determine whether GFP levels correlated with the
production of new infectious virus particles, the medium was
collected and subjected to plaque assay on BHK21 (for VSV) or
Vero (for SeV) cells. Virus titration analysis showed a clear
correlation between GFP signal and the number of infectious virus
particles produced in different cell lines under various treatment
conditions (Fig. 1C).
Next, we examined a possibility that a higher sensitivity of VSV
and SeV to RBV in 4T1, BSRT7, HeLa and HEp2 was due to the
increased cellular toxicity of RBV in these cell lines, which could
result in the decreased ability of these cells to efficiently support
viral replication. To address this issue, we used three different
assays to measure cell viability using cells prepared and RBV-
treated the same way as for virus infections shown in Figure 1: i)
colorimetric MTT assay based on the reduction of the yellow
tetrazolium salt MTT to the insoluble purple formazan crystals,
which are solubilized by the addition of a detergent in
metabolically active cells (Fig. 2A); ii) luminescent ‘‘CellTiter-
Glo’’ assay based on quantitation of the intracellular ATP content
as an indicator of metabolically active cells (Fig. 2B); iii) live cell
counting using trypan blue dye exclusion as an indicator cell
membrane integrity in the live cells (Fig. 2C). Using these three
different methods (as described in Materials and Methods), we
showed that RBV treatment even at 1000 mM concentration did
not produce any statistically significant decrease in cell viability in
any of the tested cell lines under our experimental conditions
(Fig. 2), indicating that the observed pattern of RBV antiviral
activity was not due to the differential RBV cytotoxicity in the
tested cell lines (Fig. 2). To prepare cells for these assays, 80%
confluent cells were treated with RBV for 24 h (same conditions
used for virus infections in Figure 1). After 24 h treatment, all
tested cell lines reached 100% confluence suggesting that RBV did
not produce any substantial cytotoxicity that would prevent cell
growth. However, we recognize that the cell viability assays
conducted on 100% confluent cells may not be sensitive enough to
detect all adverse effects of RBV on the host cell. Nevertheless, the
absence of significant drop in cell viability by 3 independent assays
were in good agreement with the lack of visible differences
between RBV treated and untreated cells using light microscopy
(Figure 1B and data not shown).
All infection experiments described above were conducted at
MOI of 3 CIU/cell to achieve one-step replication of viruses in all
testedcelllines.Wealsoconductedadditionalexperimentswithcells
infected at MOI 0.2, 0.5, 1, 10 or 20 in the presence of increasing
concentrations of RBV (same range as above) and observed a
similar pattern of RBV resistance in Vero, BHK21 and A549,
indicating that this effect was MOI independent (data not shown).
To further confirm the MOI-independent character of RBV
resistance in Vero, BHK21 and A549 cells, we conducted a plaque
reduction assay in the presence of RBV, which also allowed us to
calculate the 50% and 90% inhibitory concentrations (IC50 and
IC90) of RBV for each virus/cell type combination, as described in
Materials and Methods. As shown in Figure 3 and summarized in
Table 2, the IC50 and IC90 values were in good agreement with our
data using MOI 3 infections (Fig. 1). We find especially striking
resistance of Vero cells to RBV with IC50=2250mM for VSV and
1550 mM for SeV and IC90.3000 mM for both viruses. Compared
toSeV,VSVwasconsistentlymoreresistanttoRBVinalltestedcell
lines, which might be associated with its markedly faster growth in
all tested cell lines (addressed below). Nevertheless, the similar cell
type dependent pattern of RBV resistance for VSV and SeV
suggests that cellular determinants play a major role in RBV
resistance.
Analysis of RBV uptake in different cell lines
A recent study by Ibarra and Pfeiffer (2009) showed that the
development of cell-based resistance to RBV treatment via
decreased RBV uptake can greatly limit RBV antiviral activity.
Therefore, we wanted to examine a possibility that the RBV
resistance of Vero, BHK21 and A549 cells was a result of defective
RBV uptake in these cell types, using methodology similar to that
described previously [16]. To measure RBV short-term uptake,
cells were treated with SFM (same media type used for infections
but without virus) containing 50 mM RBV (1% of which was
[
3H]RBV). After 15-minute incubation, cells were collected and
measured for the level of [
3H]RBV uptake normalized to the
number of cells as described in Materials and Methods. As shown
in Figure 4A (black bars), all tested cell lines showed somewhat
similar levels of RBV import after 15-minute incubation,
indicating that none of the tested cell lines was defective in RBV
uptake. To confirm that the slightly lower [
3H]RBV counts
presented in Figure 4A for BHK21, A549, and Vero cells reflect
active uptake of RBV into the cells (rather than background
counts), we also analyzed RBV uptake in cells pretreated with
increasing concentrations of nitrobenzylthioinosine (NBMPR), a
specific inhibitor of equilibrative nucleoside transport via ENT1
(inhibited at lower NBMPR concentrations) and ENT2 (inhibited
at higher NBMPR concentrations) nucleoside transporters, which
were (especially ENT1) previously shown to be primarily
responsible for RBV import into the cells [28,29]. Our results
clearly showed RBV uptake was inhibited in most cell lines at both
lower (15 mM) and higher (100 mM) NBMPR concentrations
(Fig. 4A), confirming that ENT play at least some role in the influx
of RBV into all tested cell types. Interestingly, we were unable to
see any additional decrease of RBV uptake in 4T1 cells at the
higher NBMPR concentration (100 mM) where both ENT1 and
ENT2 are inhibited [16]. However, a decrease was observed at
Table 1. Relative number of infectious virus particles added
























Most experiments in this study were conducted using 24-well tissue culture
plates and nearly 100% confluent cells treated with RBV in SFM (or mock-
treated with SFM) and infected with VSV-GFP or SeV-GFP (or mock-infected
with SFM) at MOI of 3 CIU/cell of the tested cell line. The MOI of 3 CIU/cell for
each virus/cell type combination was calculated by infecting each cell line with
serial dilutions of VSV-GFP or SeV-GFP virus stock in SFM and counting
infectious foci with the aid of fluorescence microscopy (see Figure 7A). VSV
CIU
BHK – number of cell infectious units (infectious particles) determined by
titration of VSV-GFP virus stock on BHK21 cells. SeV CIU
HeLa - number of cell
infectious units calculated by titration of SeV-GFP virus stock on HeLa cells.
doi:10.1371/journal.pone.0011265.t001
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in the RVB uptake in this cell line.
While our short-term uptake experiments did not reveal any
defects in RBV import in the seven cell lines, we wanted to see
whether long-term accumulation of [
3H]RBV, which depends on
the RBV metabolism) was different in the seven cell lines. To test
it, we conducted a similar uptake experiment described above but
with cells treated with [
3H]RBV for 1 h, 16 h and 24h (instead of
15 minutes). As shown in Figure 4B, dramatic variations were
observed in the long-term accumulation of RBV in different cell
types. Importantly, it correlated with the antiviral efficacy of RBV
in the tested cell lines. Thus, all 3 RBV-resistant cell lines, BHK21,
A549 and especially Vero showed markedly decreased levels of
RBV accumulation suggesting that such the differences in the
intracellular RBV metabolism may be responsible for natural
resistance of BHK21, A549 and Vero cells to antiviral RBV
treatment [16].
Neutralizing effect of guanosine and actinomycin D
addition on the antiviral activity of RBV
One of the major proposed mechanisms of RBV antiviral action
is the inhibition of the host enzyme IMPDH essential for the de
novo synthesis of GTP. Moreover, a recent study suggests that
inhibition of IMPDH and the consequent decrease in the cellular
GTP pool (but not interactions of RBV metabolites with viral
polymerase) is the predominant mechanism of action of RBV
against RSV (a paramyxovirus) [30]. To examine whether RBV
inhibits VSV and SeV in all seven tested cell lines primarily via
depletion of the GTP pool, we analyzed the effect of exogenously
added guanosine on the antiviral effect of RBV. If GTP depletion
alone is sufficient for inhibition of viral replication, we expected
complete neutralization of the RBV effect in cells treated with a
combination of RBV (500 mM) and guanosine (50 mM). The
selected 50 mM guanosine concentration should result in dramatic
increase in the intracellular GTP levels. According to previous
studies, even 10 mM exogenous guanosine produces at least 4-fold
excess of physiological GTP levels within Vero, HepG2, MDCK
and other cell lines [30,31,32]. Cells were infected with either
VSV-GFP or SeV-GFP at MOI of 3 CIU/cell, and then mock-
treated or treated with the SFM containing RBV or guanosine, or
RBV together with guanosine. The intensity of GFP-associated
fluorescence attributable to viral replication was quantified (as
described in Materials and Methods) at 18 h p.i for VSV and 24 h
p.i for SeV (Fig. 5). As expected, guanosine treatment alone had
no significant effect on virus replication (Fig. 5) in most cell lines. It
had also a clear neutralizing effect on RBV in BHK21 and A549
cells, already highly resistant to RBV (Fig. 5). Intriguingly,
guanosine had an intermediate neutralizing effect in BSRT7 cells
for VSV and a very small effect on RBV activity in the RBV-
sensitive HeLa, 4T1 and HEp-2 (and BSRT7 for SeV) cells (Fig. 5),
although all tested cell lines had somewhat similar levels of [
3H]-
guanosine uptake (data not shown). The addition of 50 mM
guanosine was unable to neutralize the RBV effect in these 4 cell
lines even when the RBV concentration was lowered to 200 or
100 mM (data not shown). Also, a similar result was obtained when
200 mM guanosine was added to the medium (data not shown).
These data suggest that a decrease in the cellular GTP pool is not
the predominant mechanism of RBV action against VSV and SeV
in HeLa, 4T1, HEp-2 and BSRT7 cells, and that other
Figure 2. Effect of RBV on cell viability of seven cell lines. To
determine the relative toxicity of increasing concentrations of RBV in
different cell lines, 80%-confluent uninfected cells were treated with
RBV for 24 h and tested for viability using MTT cell viability assay (A) or
CellTiter-Glo Luminescent Cell Viability Assay (B) or by cell counting
using trypan blue dye exclusion as an indicator of live cells (C) as
described in Materials and Methods. To determine the sensitivity of the
MTT assay, serial dilutions of A549 and HeLa cells were plated [lower left
and right graphs in (A)], grown for 24 h, cells from separate wells were
trypsinized and counted using a hemocytometer (36,000 cells for HeLa
and 38,000 cells for A549 formed 100% confluent monolayers), and MTT
assay was conducted as described in Materials and Methods. (A–C) The
data (done in triplicate) represent the mean 6 standard deviation and
are expressed as a percentage of the untreated control. Statistical
analysis was done using one-way ANOVA with Tukey’s post hoc test
(GraphPad Prism 4, San Diego, CA). ***P,0.001, **P,0.01, *P,0.05, as
compared to mock-treated cells (indicated as 0 mM RBV).
doi:10.1371/journal.pone.0011265.g002
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viruses in those cell lines.
Previous studies showed that actinomycin D (ActD), an inhibitor
of DNA-primed RNA synthesis (but not viral RNA-dependent
RNA synthesis), was able to revert the antiviral effect of RBV
against several RNA viruses, including VSV [17], RSV [33],
Sindbis virus [34] and rotavirus [35]. Two mechanisms of such
reversion were proposed including the stabilization of cellular
GTP levels [17,33,34,35] and inhibition of ribavirin triphosphate
(RTP) production [33]. To examine whether RBV neutralization
by ActD can be also reproduced in case of SeV and whether it is
cell type dependent, we infected cells with VSV-GFP or SeV-GFP
at MOI 3 CIU/cell and treated these cells with ActD (5 mg/ml) or
RBV (500 mM) alone or with both drugs together at 1 h p.i.
Photographs of infected cells were taken at 24 h p.i. and the media
from each well was collected and titered to determine the number
of new infectious particles produced. As shown in Figure 6 (A–C),
ActD had a clear neutralizing effect on RBV in most cell lines,
while it had a somewhat mild effect on viral replication when used
alone in most cell lines with the strongest negative effect observed
in HEp2 cells for SeV and HeLa cells for VSV. The tolerance of
both viruses to ActD treatment is consistent with a relative
independence of their exclusively cytoplasmic replication cycle on
new mRNA synthesis by cellular RNA polymerase II, a target of
ActD. To rule out a possibility that ActD treatment affected RBV
import into the cells, all seven cell lines were treated with ActD (or
mock-treated) for 2 h followed by a [
3H]RBV uptake experiment
conducted as described in Materials and Methods. Our results
showed that ActD treatment did not inhibit RBV uptake, but
actually resulted in a slight increased uptake of RBV (data not
shown), demonstrating that the observed reversal of RBV antiviral
action (Fig. 6) was not due to the interference of ActD with RBV
uptake.
Resistance of cell lines to RBV and their ability to support
viral replication
As noted, the seven cell lines used in this study were selected
solely based on their ability to support replication of VSV and
SeV. To assess any possible correlation between the general
ability of these viruses to replicate in these cell lines and their
resistance to RBV, we compared VSV and SeV for their ability to
initiate infection and for their replication kinetics in these cell
lines without RBV treatment. First, VSV-GFP or SeV-GFP virus
stocks were titrated in parallel on different cell lines and the
relative ability of each virus to initiate virus infection was
calculated by counting infectious foci generated on each cell line.
As shown in Figure 7A (and Table 1 with the numbers calculated
based on the Figure 7A data), Vero, BHK21 and A549 cells, all
highly resistant to RBV, were among the four cell lines most
susceptible to VSV infection. Consequently, for our MOI 3
infections described in Figures 1, 3, 5 and 6, to achieve VSV
MOI 3 infection for each cell line, for each 3 ml of the VSV-GFP
virus stock added to the RBV-resistant BHK21 cells (13.2 mlt o
A549, 23.7 ml to Vero), 227 ml of the same stock was added to the
RBV-sensitive 4T1 and HEp2 and 132 ml to HeLa cells (Table 1).
However, RBV-sensitive BSRT7 cell line was found to be as
susceptible to VSV as the most RBV-resistant Vero cells
(Figure 7A and Table 1). In case of SeV, most cell lines (except
for 4T1) showed somewhat similar rates of viral infection
initiation for SeV, without any strong correlation with RBV
sensitivity (Figure 7A and Table 1).
We also conducted one-step growth kinetics analysis by infecting
each cell type with VSV-GFP or SeV-GFP at MOI of 3 CIU/cell
(MOI was calculated individually for each virus/cell type
combination) and measuring production of new infectious particles
by collecting medium from each well at specified time points and
titrating it as described in Materials and Methods. While some
correlation can be seen in SeV with its fastest growth kinetics (and
highest titers) in BHK21, A549 and Vero cells (all three resistant to
RBV), it is less apparent in the case of VSV, which grows relatively
similarly in most cell lines (Fig. 7B). Together, all these results
show no clear correlation between abilities of cell lines to support
viral replication and their resistance to RBV, although the abilities
of cells to support robust virus replication may be an important
factor that would allow successful replication in the presence of
RBV as all three RBV-resistant cell lines supported high
replication levels of both VSV and SeV. Nevertheless, our results
show that virus growth phenotype alone (e.g., VSV in BSRT7)
cannot be used to predict efficacy of RBV against VSV or SeV in a
given cell line.
Discussion
In this study, we compared the antiviral activity of RBV against
two prototypic members of the order Mononegavirales, VSV (a
rhabdovirus) and SeV (a paramyxovirus), in seven different cell
lines originated from various hosts and tissues. Previous studies
showed that RBV can effectively inhibit replication of VSV
[17,18,19] and SeV [20,21] as well as other members of
Mononegavirales [17,18,19,30,33,36,37,38,39,40]. However, in most
Figure 3. Plaque reduction assay to determine RBV inhibitory concentrations. Cell monolayers were infected with VSV-GFP or SeV-GFP (or
mock-infected; 0 mM RBV) using virus dilutions producing about 100 virus (‘‘100%’’) on each cell line in the absence of RBV, overlaid with SFM
containing 1.2% Avicel RC-581 and increasing concentrations of RBV (note that different RBV concentrations were used for each virus-cell type
combination). Cells were then incubated for 24 h (VSV) or 48 h (SeV), and plaques were counted with the aid of fluorescence and bright field
microscopy. ‘‘0%’’ indicates that no fluorescent infectious foci were detected. Each experiment was performed at least twice (done in duplicates) and
data points represent the mean 6 standard deviation.
doi:10.1371/journal.pone.0011265.g003
Table 2. Antiviral activity (IC50 and IC90) of RBV against VSV
and SeV in different cell types.
Cell type IC50 (mM) IC90 (mM) IC50 (mM) IC90 (mM)
VSV-GFP SeV-GFP
BHK21 275 1100 190 850
BSRT7 10 40 16 40
HeLa 70 150 40 110
A549 190 610 90 320
4T1 20 60 10 18
HEp2 70 310 12 45
Vero 2250 .3000 1550 .3000
The 50% and 90% inhibitory concentrations (IC50 and IC90) for RBV were
estimated by means of the plaque reduction (Fig. 2) as described in Materials
and Methods. Data are expressed as mean without standard error of mean that,
however, never exceeded 20% of the mean values. Note that an extremely poor
potency of RBV against VSV and SeV in Vero did not allow it to reach IC90 even
at 3000 mM RBV concentration (‘‘.3000’’).
doi:10.1371/journal.pone.0011265.t002
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seven cell lines used in this study were selected solely based on
their ability to support replication of both viruses. The two-virus
approach allowed us to discriminate between virus specific and
cell-based resistance to RBV treatment because, although both
viruses belong to the same order Mononegavirales, they belong to
different families and have noticeably different growth kinetics in
these cell lines.
Figure 4. RBV uptake and its inhibition in different cell lines. (A) Cell monolayers on 24-well plates (done in triplicates) were pretreated for
15 minutes with 15 or 100 mM NBMPR/DMSO or mock-treated with the same amount of DMSO as contained in the treated wells. Cells were then
treated with SFM containing 50 mM RBV 1% of which was [
3H]RBV for 15 minutes at 37uC. Nucleotide pools were isolated and measured for [
3H] as
described in Materials and Methods. Uptake values represent CPM divided by number of cells in a 24-well plate and normalized to the uptake by
DMSO-treated BHK21 cells (defined as 100%). The mean 6 standard deviation is shown for four independent experiments (done in triplicates). (B)
Cells monolayers (done in triplicates) on 12-well plates were treated with SFM containing 50 mM RBV 1% of which was [
3H]RBV (without uptake
inhibitors) at 37uC for 1 h, 16 h or 24 h. Nucleotide pools were isolated and measured for [
3H] as described in Materials and Methods. Uptake values
represent CPM divided by number of cells in a 12-well plate and normalized to the uptake by BHK21 cells for 1 h (defined as 100%). The mean 6
standard deviation is shown for two independent experiments (done in triplicates). (A–B) Statistical analysis was done using one-way ANOVA with
Tukey’s post hoc test (GraphPad Prism 4, San Diego, CA). ***P,0.001, **P,0.01, *P,0.05, as compared to RBV only treated cells (A) or cells treated
with RBV for 1 h (B).
doi:10.1371/journal.pone.0011265.g004
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from the extremely poor antiviral activity of RBV in Vero cells
(e.g., IC50=2250 mM for VSV and 1550 mM for SeV;
IC90.3000 mM for both viruses), moderate activity in BHK21
and A549 cells, and very effective inhibition in HEp2, HeLa, 4T1
and BSRT7 cells (IC50=10mM, IC90=40mM for VSV in
BSRT7; IC50=16mM, IC90=40mM for SeV in BSRT7). This
pattern was confirmed using various infection and RBV treatment
conditions, with cells infected and treated at 34 or 37uC, high or
low MOI, and with RBV treatment starting at 24 h before
infection, 6 h before infection, or 1 h p.i. Using three different cell
viability assays, we showed that RBV treatment even at 1000 mM
concentration did not produce any significant cytotoxicity in any
of the tested cell lines at our experimental conditions, nor did we
observe any significant differences between tested cell types,
indicating that the observed pattern of RBV resistance was not due
to differences in RBV toxicity. It is important to emphasize that
the median RBV plasma concentration in HCV patients at the
peak of RBV therapy is between 6.6and 9 mM [41,42,43,44].
Therefore, the IC50 and IC90 values for Vero, BHK21 and A549
cells (Table 2) indicate extremely high resistance of these cell types
to RBV.
Our data strongly argue that the observed resistance of VSV and
SeV to RBV in Vero, BHK21 and A549 was not due to the
generation of RBV-resistant mutants in these cells. Such ‘‘virus-
based’’ resistance mechanism was previously described for several
other RNA virus groups, including polioviruses [5,12], foot-and-
mouth disease virus [13,14] and recently for HCV [45]. However,
even when our cells were treated with RBV starting as early as 24 h
before infection (Fig. 1), we observed little effect of RBV on viral
replication in RBV-resistant cells, ruling out any possibility of virus
adaptation to RBV. In addition, when VSV was passed 10 to 15
times in HeLa, BSRT7 and BHK21 cells in the presence of sub-
inhibitory RBV concentrations, no viral adaptation to RBV was
Figure 5. Effect of exogenously added guanosine on antiviral activity of RBV. Cells were mock infected or infected with either VSV-GFP or
SeV-GFP at MOI of 3 CIU/cell, and then mock-treated or treated with SFM containing 500 mM RBV, 50 mM guanosine, or both. The intensity of GFP
fluorescent signal at 18 h p.i for VSV (A) and 24 h p.i for SeV (B) was quantified using a 96-well plate reader, as described in Materials and Methods.
Each of these experiments was performed twice (done in triplicates) and data points represent the mean 6 standard deviation. (A–B) Statistical
analysis was done using one-way ANOVA with Tukey’s post hoc test (GraphPad Prism 4, San Diego, CA). ***P,0.001, **P,0.01, *P,0.05 are shown to
compare RBV plus guanosine treatment against RBV treatment only.
doi:10.1371/journal.pone.0011265.g005
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observations are consistent with a previous study by Cuevas et al.
(2005) demonstrating that even after 100 generations under sub-
inhibitory concentrations of RBV, resistance of VSV to RBV was
not achieved, with selected populations generally less fit than the
ancestral population both in the presence and absence of RBV [19].
A recent study by Ibarra and Pfeiffer [16] showed that the
development of cell-based drug resistance after continuous RBV
treatment via decreased drug uptake can greatly limit RBV
efficacy. In addition, any potential antiviral mechanism absolutely
relies on RBV entry into the cell. Therefore, we compared our
seven cell lines for their ability to internalize RBV. Our results
showed a similar RBV uptake in all tested cell lines after 15-minute
treatment, indicating that none of the tested cell lines was defective
in RBV uptake. In addition, using NBMPR, a specific inhibitor of
equilibrative nucleoside transporters, we confirmed that ENT1
and possibly ENT2 transporters are involved in the RBV uptake
[29,46]. A similar RBV uptake level by all tested cell lines is not
surprising as ENTs are ubiquitously expressed in virtually all cell
types [49]. However, when we analyzed long-term RBV
accumulation in cells after 16 h or 24 h treatment, a totally
different picture was observed. Four cell lines sensitive to RBV
(BSRT7, HeLa, HEp2 and 4T1) showed significantly higher levels
of RBV accumulation compared to RBV-resistant BHK21, A549
and Vero. Vero cells had particularly low accumulation which
may explain the highest resistance of this cell line to RBV
treatment among all the cell lines tested in our study (Table 2).
It is important to note that while the 15-minute uptake assay
determines the ability of cells to internalize RBV, the long-term
accumulation is dependent on the cellular metabolism of RBV.
Neutral RBV molecule can be transported freely in and out of a
cell via ENTs, but once it is phosphorylated, negative-charged
RMP, RDP, or RTP are trapped inside the cells. A good
illustration of the difference between the RBV uptake and its long-
term accumulation is RBV hyperaccumulation in erythrocytes
resulting in haemolytic anemia in some RBV-treated patients.
Similarly to nucleated cells, RBV is transported into erythrocytes
via ENTs [46] and converted into RMP, RDP and RTP.
However, unlike nucleated cells, they lack the phosphatases
needed to hydrolyze RMP/RDP/RTP into RBV [47,48,49].
Recent study by Endres et al. (2009) directly showed that total
radioactivity of RBV after long-term administration is predomi-
nantly attributed to RMP and RTP [49]. Hyperaccumulation of
these molecules, along with other factors, results in cellular toxicity
of erythrocytes and subsequent anemia [47].
While future studies are warranted to directly analyze RBV
metabolism in the seven cell lines, our results indicate that these
cell lines may significantly differ in their abilities to accumulate
sufficient amounts of phosphorylated RBV metabolites required
for effective RBV antiviral actions. RMP is believed to play the
major antiviral role as a competitive inhibitor of the enzyme
IMPDH essential for the de novo synthesis of GTP and is also
capable of binding and inhibiting at least some viral polymerases
[2], including viral polymerase of VSV [17,18,19]. RTP may also
play an important role in the inhibition of VSV and SeV
replication via interaction with viral polymerase (shown for RTP
and VSV [18]), ‘‘error catastrophe’’ or any other mechanisms
which involves RTP as a substrate for viral RNA polymerase.
To examine whether RBV inhibits VSV and SeV primarily via
depletion of the GTP pool, we treated VSV or SeV infected cells
with RBV in the presence of extracellular guanosine which restores
normal intracellular GTP level. Guanosine had a clear (almost
100%) neutralizing effect on RBV in BHK21, A549 and Vero cells,
which are already highly resistant to RBV. However, very little
effect was observed on the RBV activities in RBV-sensitive cells,
especially HeLa, 4T1 and HEp-2 cells. Together, these data suggest
that a decrease in the cellular GTP pool is not the predominant
mechanism of RBV action against VSV and SeV in HeLa, 4T1,
HEp-2and BSRT7cells,and thatothermechanismsalsocontribute
to RBV activity against these two viruses in these cell lines.
Figure 6. Effect of ActD on antiviral activity of RBV. Cell
monolayers were infected with SeV-GFP (A) or VSV-GFP (B) at MOI 3
CIU/cell in the absence of drugs, or with 5mg/ml ActD, 500 mM RBV, or
both. Fluorescence (upper panels) and light (lower panels) microscopy
images were captured at 106 magnification. The photographs are
typical representations of at least three independent experiments and
an average field for each well is shown. (C) The number of new
infectious VSV-GFP particles generated in the wells photographed in (B)
was determined by analysis of SFM collected from each well by plaque
assay on BHK21 cells (done in duplicates, average is shown).
doi:10.1371/journal.pone.0011265.g006
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in all tested cell lines. Previous studies showed that ActD
neutralizes RBV effects via two mechanisms (likely not mutually
exclusive). Malinoski and Stollar (1980) showed that ActD
neutralized effect of RBV against Sindbis virus by maintaining
the GTP pool size at its normal level (the mechanism of this
stabilization is still unknown) [34]. A similar effect of ActD on
GTP pool stabilization was shown by Smee and Matthews (1986)
in RSV-infected cells treated with RBV. However, they also
analyzed the metabolism of RMP to its mono-, di-, and
triphosphate derivatives in uninfected and RSV-infected cells,
and concluded that ActD also neutralized RBV effect via
inhibition of RTP production [33].
Based on the ability of ActD (but not guanosine) to neutralize the
effect of RBV in RBV-sensitive cell lines (HeLa, 4T1, HEp-2 and
BSRT7), we hypothesize that RBV antiviral activity in these cell
lines depends not only on the depletion of the GTP pool (can be
restored by guanosine addition) but also on the successful 59-
phosphorylation of RBV into RMP/RDP/RTP [9,10,11], which
were previously shown to inhibit VSV RNA synthesis in vitro [18].
Atthesame time,wethinkthat RBV acts inRBV-resistant celltypes
(BHK, A549 and Vero) primarily via depletion of GTP pool due to
insufficient amounts of phosphorylated RBV molecules in these
cells, explaining why the effect of RBV can be completely reversed
in these cell lines by guanosine. Further experiments are planned to
test this hypothesis and further investigate the mechanism of RBV
neutralization by ActD. Overall, our data point out to an interesting
possibility that the mechanism of virus inhibition by RBV may be
more dependent on cell type than we currently expect. This could
explain numerous conflicting reports regarding the ‘‘true’’ mech-
anism of RBV action proposed by different research groups for the
same virus [2,3,4,5]. Furthermore, we anticipate that different
results for other viruses might be obtained in the cell lines utilized
here. For example, a recent study demonstrated an effective
inhibition of canine distemper virus (CDV, family Paramyxoviridae,
genus Morbillivirus) in Vero cells [IC50=20–50 mM, IC80=40–
110 mM] [39]. This result suggests that CDV and SeV might be
inhibited by RBV via different mechanisms.
At present, we cannot explain dramatic differences between
BHK21 and BSRT7 cells in their resistance to RBV and the long-
term RBV accumulation. BSRT7 cell line is derived from BHK21
and constitutively express bacteriophage T7 polymerase under
control of the cytomegalovirus promoter and the neomycin
resistance gene [22]. Although we cannot explain why these two
celllinesaresodifferentinregardtoRBV,wealsonoticedsignificant
differences in cell appearance, cell growth kinetics, viral growth
kinetics and the phenotype of infectious foci for VSV and SeV
between BHK and BSRT7 cells (data not shown), suggesting that
someadditionalchanges were introduced into BSRT7whenorsince
this recombinant cell line was generated, or that T7 polymerase
expression may be responsible for some or all of those phenotypes.
We believe the very similar pattern of RBV activity against VSV
and SeV in seven different cells lines may indicate that these two
viruses are inhibited by RBV via the same mechanism. Although
Figure 7. Viral infectivity and replication kinetics in the seven cell lines. (A) Cells were infected with serial dilutions of VSV-GFP (left) or SeV-
GFP (right), and infectious foci were counted to calculate the infectivity of the viral stock for each cell line. (B) One-step kinetics of viral replication in
seven cell lines. Cells were infected in parallel with VSV-GFP or SeV-GFP at MOI of 3 CIU/cell (1 h absorption), washed 3 times with PBS, and kept in
SFM. The media containing newly generated virions was collected at the indicated time points and viral titrations were performed on BHK21 (for VSV)
or Vero cells (for SeV).
doi:10.1371/journal.pone.0011265.g007
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not been previously studied, a previous study on RSV (another
member of the family Paramyxoviridae, but belongs to the genus
Pneumovirus) suggests the predominant mechanism of action of
RBV against RSV is inhibition of cellular IMPDH activity by
RMP (and consequent decrease in the cellular GTP pool) rather
than interactions of RBV metabolites with the viral polymerase
[30]. In contrast, a previous study using in vitro transcription
reactions with purified VSV virions demonstrated that RMP, RDP
and RTP significantly inhibited viral polymerase activity and
hypothesized that these molecules reversibly inhibit an initiating
step of VSV RNA synthesis [18]. Further experiments are needed
to examine molecular mechanisms of VSV and SeV inhibition by
RBV.
Overall, our data demonstrate the antiviral activity of RBV is
naturally limited in many cell types which may explain at least
some RBV treatment failures. Further studies aimed at the
understanding molecular determinants responsible for cell-based
resistance to RBV are warranted. This understanding may
become an important tool for tailoring individualized treatments
with RBV (and possibly other nucleoside analogs) against
important viral pathogens. Future experiments are also needed
to determine whether the observed differences between different
cell lines are limited only to nonsegmented negative-strand RNA
viruses by analyzing effect of RBV on replication of positive-strand
RNA or segmented negative-strand RNA viruses in these cell lines.
Finally, our results strongly point out the importance of using
multiple cell lines of different origin when antiviral efficacy and
potency are examined for new as well as established drugs in vitro.
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